August 13, 2009
The observation that people taking medication for schizophrenia have lower cancer rates than other people has prompted new research revealing that anti-psychotic drugs could help treat some major cancers.
Today Merz Pharma entered the Irish Healthcare market with Denzapine, the first generic form of clozapine available in Ireland. Denzapine is an atypical antipsychotic agent used in treatment-resistant schizophrenia (TRS) which has been available to prescribe in the UK since February 2004. Denzapine is available in four tablet ...
announces, available, denzapine, first, generic, launch, merz, pharma, resistant, schizophrenia, treatment
A new study suggests that people at very high risk of developing psychotic disorders appear less likely to to do so after taking fish oil for three months. The study was conducted by Dr G Paul Amminger from the Medical University of Vienna in Austria, and the Orygen Youth ...
A blood test for diagnosing schizophrenia - the most serious form of mental illness - could be available this year, according to an article in the current issue of Chemical & Engineering News, ACS' weekly newsmagazine. The disorder, with symptoms that can include hallucinations and delusional thoughts, affects more than ...
Dainippon Sumitomo Pharma America, Inc. (DSPA), a U.S. subsidiary of Dainippon Sumitomo Pharma Co., Ltd. (DSP), submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for lurasidone, an investigational atypical antipsychotic agent for the treatment of schizophrenia. The application, submitted on December 30, 2009, includes ...
america, announces, dainippon, fda, lurasidone, nda, pharma, schizophrenia, submission, sumitomo, treatment
EnVivo Pharmaceuticals announced the initiation and dosing of patients in a Phase 2b study of its EVP-6124 compound, a selective alpha-7 nicotinic agonist in patients with schizophrenia. EnVivo is conducting the multi-center, dose ranging, placebo controlled, three-month study in the U.S. and Europe. The study is designed to determine the ...
Intra-Cellular Therapies, Inc. (ITI) announced at a recent conference on neuropsychiatric diseases the results from a recently completed Phase I clinical study demonstrating ITI-007, the Company's lead antipsychotic drug, interacts with important targets in the living human brain. These key targets are critical to drug action in many neuropsychiatric and ...
007, announces, cellular, disorders, intra, iti, pet, phase, psychiatric, schizophrenia, study, therapies, treatment
Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) announced that it has submitted its New Drug Application (NDA) for Staccato® loxapine (AZ-004) to the US Food and Drug Administration (FDA). AZ-004 is an inhalation product candidate being developed for the rapid treatment of agitation in patients with schizophrenia or bipolar disorder. The IND ...
